IDYA
IDEAYA Biosciences, Inc.Company Information
- Company Name
- IDEAYA Biosciences, Inc.
- CIK
- CIK0001676725
- Category
- Large accelerated filer
- Ticker: Exchange
- IDYA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IDYA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-02
- Last sale
- 2026-07-07
- Shares purchased (TTM)
- 50,000
- Shares sold (TTM)
- 9,550
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 100,346,806
- Shares outstanding
- 92,061,452
- Ownership
- 109.00%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 11.08%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 273 | 158 | 113 | 299 | 115 | 130 | 84 | 400 | 183 | 108 | 157 | 152 | ||||||
| Marketable Securities Current | 556 | 514 | 527 | 488 | 555 | 563 | 592 | 520 | 519 | 590 | 368 | 317 | ||||||
| Receivables Net Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 7 | ||||||
| Prepaid Expense And Other Assets Current | 20 | 18 | 21 | 16 | 16 | 15 | 13 | 12 | 12 | 11 | 8 | 7 | ||||||
| Contract With Customer Asset Net Current | 15 | 7 | 6 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 864 | 696 | 667 | 803 | 686 | 708 | 690 | 932 | 713 | 709 | 533 | 482 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Marketable Securities Noncurrent | 414 | 302 | 410 | 350 | 322 | 359 | 406 | 280 | 251 | 243 | 107 | 42 | ||||||
| Property Plant And Equipment Net | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 8 | 7 | 7 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 22 | 23 | 23 | 24 | 24 | 24 | 19 | 18 | 1 | 2 | 2 | 1 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Assets | 1,310 | 1,030 | 1,109 | 1,185 | 1,041 | 1,101 | 1,124 | 1,240 | 974 | 962 | 649 | 533 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 31 | 21 | 18 | 18 | 17 | 18 | 15 | 13 | 16 | 6 | 7 | 5 | ||||||
| Accrued Liabilities Current | 51 | 44 | 41 | 45 | 38 | 33 | 30 | 28 | 24 | 18 | 19 | 16 | ||||||
| Contract With Customer Liability Current | - | - | - | 0 | - | - | - | - | - | - | - | 1 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | ||||||
| Liabilities Current | 83 | 65 | 59 | 65 | 55 | 51 | 46 | 41 | 41 | 25 | 27 | 25 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | 2 | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 28 | 28 | 28 | 27 | 26 | 26 | 19 | 19 | 1 | 1 | 1 | - | ||||||
| Liabilities | 111 | 93 | 86 | 93 | 82 | 77 | 65 | 59 | 42 | 26 | 28 | 25 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,148 | 1,773 | 1,757 | 1,743 | 1,731 | 1,718 | 1,681 | 1,669 | 1,374 | 1,324 | 969 | 823 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -0 | 2 | 2 | 2 | 2 | 1 | 4 | -1 | -1 | 1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -948 | -835 | -737 | -653 | -773 | -695 | -623 | -493 | -441 | -388 | -348 | -314 | ||||||
| Stockholders Equity | 1,199 | 937 | 1,023 | 1,092 | 960 | 1,024 | 1,059 | 1,180 | 932 | 935 | 621 | 508 | ||||||
| Liabilities And Stockholders Equity | 1,310 | 1,030 | 1,109 | 1,185 | 1,041 | 1,101 | 1,124 | 1,240 | 974 | 962 | 649 | 533 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 96 | 88 | 88 | 88 | 88 | 88 | 87 | 86 | 76 | 75 | 65 | 59 | ||||||
| Shares Outstanding | 96 | 88 | 88 | 88 | 88 | 88 | 87 | 86 | 76 | 75 | 65 | 59 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIDEAYA Biosciences, Inc. (IDYA) — SEC Financial Statements & Analysis
IDEAYA Biosciences, Inc. (IDYA) is a pharmaceutical preparations company, incorporated in DE. IDEAYA Biosciences, Inc. trades on Nasdaq as: IDYA. IDEAYA Biosciences, Inc. (IDYA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, IDEAYA Biosciences, Inc. carries a market cap of $3.43B, a P/E ratio of -19.60x, a P/B ratio of 2.86x, a P/S ratio of 14.65x, an enterprise value of $3.16B, and an EV/EBITDA multiple of -14.74x. On profitability, it posts an operating margin of -92.66%, a net margin of -74.75%, a Return on Equity (ROE) of -16.22%, a Return on Assets (ROA) of -14.89%, and a Return on Invested Capital (ROIC) of -24.46%. Per share, it reports EPS of $-1.90, diluted EPS of $-1.90, free cash flow per share of $-1.24, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 3244.67% year-over-year, net income growth of -47.25% year-over-year, and EPS growth of -49.31% year-over-year. On the balance sheet, it maintains a current ratio of 10.45x, a quick ratio of 10.21x, working capital of $781.35M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-113.87M (TTM), and net debt of $-273.87M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.43B
- P/E TTM
- -19.60x
- EPS TTM
- $-1.90
- P/B TTM
- 2.86x
- ROE TTM
- -16.22%
- ROA TTM
- -14.89%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-113.87M
- Net Revenue TTM Growth 1Y
- 3244.67%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IDEAYA Biosciences, Inc. in?
IDEAYA Biosciences, Inc. (IDYA) operates in the Pharmaceutical Preparations industry.
What exchange does IDYA trade on?
IDEAYA Biosciences, Inc. (IDYA) trades on the Nasdaq.
Where is IDEAYA Biosciences, Inc. incorporated?
IDEAYA Biosciences, Inc. is incorporated in DE.
When was IDEAYA Biosciences, Inc. (IDYA)'s most recent SEC filing?
IDEAYA Biosciences, Inc. (IDYA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is IDYA's market cap?
IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $3.43B as of 2026-06-30.
What is IDYA's EPS (earnings per share)?
IDEAYA Biosciences, Inc. (IDYA)'s trailing twelve month EPS is $-1.90 as of 2026-06-30.
What is IDYA's ROE (return on equity)?
IDEAYA Biosciences, Inc. (IDYA)'s trailing twelve month Return on Equity (ROE) is -16.22% as of 2026-06-30.
What is IDYA's ROA (return on assets)?
IDEAYA Biosciences, Inc. (IDYA)'s trailing twelve month Return on Assets (ROA) is -14.89% as of 2026-06-30.
What is IDYA's ROIC (return on invested capital)?
IDEAYA Biosciences, Inc. (IDYA)'s trailing twelve month Return on Invested Capital (ROIC) is -24.46% as of 2026-06-30.
What is IDYA's EV/EBITDA?
IDEAYA Biosciences, Inc. (IDYA)'s trailing twelve month EV/EBITDA is -14.74x as of 2026-06-30.